Rakovina partners with Celvion to apply AI to ATR program

Rakovina Therapeutics said it has a research collaboration with Celvion Therapeutics to use Celvion’s EMphora AI and real-world data to identify combination therapies, biomarkers, and patient subgroups for Rakovina’s ATR inhibitor program.